SCHLIEREN, Switzerland – (BUSINESS WIRE) – May 17, 2021 –
Memo Therapeutics AG (“Memo”), an innovator in antibody discovery and development, today announced that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus responsible for COVID-19, has shown its effectiveness against the original virus as well as the British variant (B.1.1.7). Memo is currently preparing MTX-COVAB for clinical evaluation.
Using its microfluidic molecular cloning and single-cell molecular screening technologies to enable antibody repertoire extraction and antibody discovery, Memo can discover new antibodies at unprecedented speed, efficiency and sensitivity derived from patient samples recovered. This approach has also enabled the company to identify a very promising antibody candidate against the South African variant (B.1.351).
Memo is collaborating with the Serum Institute India and prestigious academic partners in Austria, Brazil and South Africa to collect patient samples in the coming weeks to enable the isolation of promising and effective antibodies against each of the variants. This can be done in as little as 3 weeks after receiving the blood sample.
“The fight against SARS-CoV-2 variants remains a global challenge and will remain. Vaccines will not always be effective against all variants, so the ability of our technology to quickly identify active antibodies could be an additional strategy to combat the spread of these mutant strains, ”said Dr Christoph Esslinger, CSO and co-founder of Memo.
“Memo’s ability to discover potent antibodies against COVID variants in such a short time demonstrates the power and wide applicability of our technology,” said Dr. Karsten Fischer, CEO of Memo Therapeutics AG. “We look forward to working with colleagues in India, Austria, South Africa and Brazil to apply this powerful approach to these new strains that are difficult to control.
The clinical development of MTX-COVAB is advised by Vakzine Projekt Management GmbH.
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. The company’s antibody discovery platform uses robust, simple, and rapid microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire extraction and antibody discovery at speed, efficiency. and unprecedented sensitivity.
The platform captures and preserves entire repertoires of B cells from any donor species and any type of B cell in recombinant form for display using mammalian cells. The antibody repertoires are then screened in single-cell format using microfluidic screening technology that can assess millions of candidate antibodies directly in functional assays, resulting in clonal recombinant cell lines expressing monoclonal antibodies (mAbs) with the desired functional properties.
Harnessing the power of its single-cell microfluidic molecular cloning and screening technologies, Memo Therapeutics AG engages in the discovery of antibodies across species and indications for both proprietary and partnership projects. The company’s current portfolio includes programs in infectious diseases and immuno-oncology. Memo Therapeutics AG is a privately held company located at Bio-Technopark Zurich, Switzerland.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210517005220/en/
CONTACT: Memo Therapeutics
Dr Karsten Fischer
[email protected] Halsin Partners
+44 (0) 7968 022075
KEYWORD: SOUTH AFRICA AFRICA SWITZERLAND UNITED STATES UNITED KINGDOM NORTH AMERICA EUROPE
INDUSTRY KEYWORD: RESEARCH MEDICAL SUPPLIES INFECTIOUS DISEASES GENETICS CLINICAL TRIALS BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH SCIENCE
SOURCE: Memo Therapeutics AG
Copyright Business Wire 2021.
PUB: 05/17/2021 03:00 / DISC: 05/17/2021 03:02
Copyright Business Wire 2021.